FDA approves cabozantinib for adults and paediatric patients 12 years of age and older with pNET and epNET
On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for…
Browsing: FDA Approvals
FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumours
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug…
FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab with…
FDA approves vimseltinib for symptomatic tenosynovial giant cell tumour
On February 14, 2025, the Food and Drug Administration approved vimseltinib, a kinase inhibitor, for…
FDA approves mirdametinib for adult and paediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
On February 11, 2025, the Food and Drug Administration approved mirdametinib, a kinase inhibitor, for…
FDA approves treosulfan with fludarabine as a preparative regimen for alloHSCT in adult and paediatric patients with AML or MDS
On January 21, 2025, the Food and Drug Administration approved treosulfan, an alkylating agent, with…
FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma
On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin in combination with…
FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer
On January 16, 2025, the Food and Drug Administration approved sotorasib with panitumumab for adult…
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma
On January 16, 2025, the Food and Drug Administration granted traditional approval to acalabrutinib with…
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk, a Trop-2-directed antibody…